These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 36647077)

  • 1. Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results.
    Forsythe E; Haws RM; Argente J; Beales P; Martos-Moreno GÁ; Dollfus H; Chirila C; Gnanasakthy A; Buckley BC; Mallya UG; Clément K; Haqq AM
    Orphanet J Rare Dis; 2023 Jan; 18(1):12. PubMed ID: 36647077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency.
    Kühnen P; Wabitsch M; von Schnurbein J; Chirila C; Mallya UG; Callahan P; Gnanasakthy A; Poitou C; Krabusch PM; Stewart M; Clément K
    Orphanet J Rare Dis; 2022 Feb; 17(1):38. PubMed ID: 35123544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl Syndrome.
    Ervin C; Norcross L; Mallya UG; Fehnel S; Mittleman RS; Webster M; Haqq AM; Haws RM
    Adv Ther; 2023 May; 40(5):2394-2411. PubMed ID: 36961653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.
    Haqq AM; Chung WK; Dollfus H; Haws RM; Martos-Moreno GÁ; Poitou C; Yanovski JA; Mittleman RS; Yuan G; Forsythe E; Clément K; Argente J
    Lancet Diabetes Endocrinol; 2022 Dec; 10(12):859-868. PubMed ID: 36356613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Burden of hyperphagia and obesity in Bardet-Biedl syndrome: a multicountry survey.
    Forsythe E; Mallya UG; Yang M; Huber C; Cala ML; Greatsinger A; Hagopian E; Pomeroy J; Haqq AM
    Orphanet J Rare Dis; 2023 Jul; 18(1):182. PubMed ID: 37415189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design.
    Haws RM; Gordon G; Han JC; Yanovski JA; Yuan G; Stewart MW
    Contemp Clin Trials Commun; 2021 Jun; 22():100780. PubMed ID: 34013094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of setmelanotide injection for chronic weight management in adult and pediatric patients with obesity due to Bardet-Biedl syndrome.
    Lazareva J; Brady SM; Yanovski JA
    Expert Opin Pharmacother; 2023 Apr; 24(6):667-674. PubMed ID: 37013719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caregiver burden in Bardet-Biedl syndrome: findings from the CARE-BBS study.
    Forsythe E; Mallya UG; Yang M; Huber C; Cala ML; Greatsinger A; Hagopian E; Pomeroy J; Haqq AM
    Orphanet J Rare Dis; 2023 Jul; 18(1):181. PubMed ID: 37415214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome.
    Haws R; Brady S; Davis E; Fletty K; Yuan G; Gordon G; Stewart M; Yanovski J
    Diabetes Obes Metab; 2020 Nov; 22(11):2133-2140. PubMed ID: 32627316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Improved Care and Treatment Options for Patients with Hyperphagia-Associated Obesity in Bardet-Biedl Syndrome].
    Cetiner M; Bergmann C; Bettendorf M; Faust J; Gäckler A; Gillissen B; Hansen M; Kerber M; Klaus G; König J; Kühlewein L; Oh J; Richter-Unruh A; von Schnurbein J; Wabitsch M; Weihrauch-Blüher S; Pape L
    Klin Padiatr; 2024 Sep; 236(5):269-279. PubMed ID: 38458231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperphagia among patients with Bardet-Biedl syndrome.
    Sherafat-Kazemzadeh R; Ivey L; Kahn SR; Sapp JC; Hicks MD; Kim RC; Krause AJ; Shomaker LB; Biesecker LG; Han JC; Yanovski JA
    Pediatr Obes; 2013 Oct; 8(5):e64-7. PubMed ID: 23776152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bardet-Biedl syndrome: A clinical overview focusing on diagnosis, outcomes and best-practice management.
    Shoemaker A
    Diabetes Obes Metab; 2024 Apr; 26 Suppl 2():25-33. PubMed ID: 38383825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity.
    Trapp CM; Censani M
    Curr Opin Endocrinol Diabetes Obes; 2023 Apr; 30(2):136-140. PubMed ID: 36722447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity.
    Kolotkin RL; Chen S; Klassen P; Gilder K; Greenway FL
    Clin Obes; 2015 Oct; 5(5):237-44. PubMed ID: 26222044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between health-related quality of life and weight loss.
    Kolotkin RL; Crosby RD; Williams GR; Hartley GG; Nicol S
    Obes Res; 2001 Sep; 9(9):564-71. PubMed ID: 11557837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a brief measure to assess quality of life in obesity.
    Kolotkin RL; Crosby RD; Kosloski KD; Williams GR
    Obes Res; 2001 Feb; 9(2):102-11. PubMed ID: 11316344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bardet-Biedl syndrome: Weight patterns and genetics in a rare obesity syndrome.
    Pomeroy J; Krentz AD; Richardson JG; Berg RL; VanWormer JJ; Haws RM
    Pediatr Obes; 2021 Feb; 16(2):e12703. PubMed ID: 32700463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity.
    Kolotkin RL; Gabriel Smolarz B; Meincke HH; Fujioka K
    Clin Obes; 2018 Feb; 8(1):1-10. PubMed ID: 29045079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric evaluation of the impact of weight on quality of life-lite questionnaire (IWQOL-lite) in a community sample.
    Kolotkin RL; Crosby RD
    Qual Life Res; 2002 Mar; 11(2):157-71. PubMed ID: 12018739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
    Kolotkin RL; Corey-Lisle PK; Crosby RD; Kan HJ; McQuade RD
    Eur Psychiatry; 2008 Dec; 23(8):561-6. PubMed ID: 18374544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.